Vivodyne

Vivodyne

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.vivodyne.com

Last Round

Series A

May 29, 2025

Total Funding Raised

$82M

Momentum Score

25 /100

Company Overview

Vivodyne is a biotechnology company that offers a microfluidic bioengineering platform for advancing single-cell 4D phenomics and facilitating drug discovery and cellular therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Biotech Equipment, Industrial Robotics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

organoidspreclinical testinglab-grown human organsanimal testing alternativedrug discovery platformtissue engineeringhuman organ modelspredictive AI modelingorgan-on-a-chiprobotics automationdrug safety testingcontract research organizationCROhigh-throughput screeningtoxicity analysisin vitro testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivodyne Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivodyne Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMay 29, 2025
SeedNov 22, 2023
SeedMar 30, 2021

Key People

Founding team and executive leadership

Andrei Georgescu

Chief Executive Officer

Executive Team

Julie O'Shaughnessy

Chief Operating Officer And Board Director

Executive Team

Vivodyne Investors

Notable investors and investment history

InvestorRounds
LingottoSeries A
Khosla VenturesSeries A, Seed
Kairos VenturesSeries A, Seed
Helena CapitalSeries A
Helena Special InvestmentsSeries A
Fortius VenturesSeries A
CS VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 29, 2025

    $40M round completed.

  • Feb 20, 2025

    Partnered with a majority of top 10 multinational pharmaceutical companies.

Vivodyne Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivodyne Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivodyne's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range39
Year Founded2020
Last FundingMay 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.